5th patent granted for WaferiXTM technology to date
Singapore, 28 September 2015 – Specialty pharmaceutical company iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a Japanese patent (no. 5777170) for its WaferiXTM drug delivery technology. The patent will expire on 26 October 2030.
The grant of the Japanese patent adds yet another feather to iX Biopharma’s cap, following its announcement last week of the success of its Phase 2a and 2b clinical trials for its oral sublingual pain management product, WafermineTM. WaferiXTM is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine or fentanyl, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. The WaferiXTM technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips, injections and oral intake. Key advantages of WaferiXTM include rapid drug absorption and onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.
The claims of the patent cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity, and provide strategic coverage for iX Biopharma’s WaferiXTM technology in Japan. According to the claims of the patent, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also provided. Japan is the fifth country which has granted iX Biopharma a patent for WaferiXTM. Counterpart patents have already been granted in Australia, Malaysia, New Zealand and Singapore; with pending applications currently under examination in the US, Canada, China, Hong Kong, South Korea, Indonesia, Thailand, Vietnam, India and Europe.
About iX Biopharma Ltd
iX Biopharma Ltd is a specialty pharmaceutical company, with initial focus on the development and commercialisation of innovative therapies for pain management and men’s health. The Company leverages its patented sublingual drug delivery technology, WaferiXTM, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. It currently has three products under development – WafermineTM and WafernylTM for pain management, and PheoniXTM, for erectile dysfunction.
Contact for media:
Ms Alvina Tan
DID: +65 6221 2123 H/P: +65 9787 7267
Email: alvina.tan@arkadvisors.com.sg
Ms Karin Lai
DID: +65 6221 0081 H/P: +65 9837 8136
Email: karin.lai@arkadvisors.com.sg
Help employers find you! Check out all the jobs and post your resume.
